Europe has expanded its dominance of hiring fintech among railway companies in the three months ending March.

The number of roles in Europe accounts for 64.3% of the total number of fintech jobs – compared to 6.1% in the same quarter last year.

This was followed by South and Central America, which saw a change of -4.1 percentage points on an annual basis in fintech roles.

The figures are compiled by GlobalData, which tracks the number of new job postings from key companies in different sectors over time. With the help of text analysis, these job postings are then classified thematically.

GlobalData’s thematic approach to sectoral activities seeks to group key company information by topic to see which companies are best placed to withstand the disruptions coming into their industries.

These key topics, which include fintech, have been chosen to cover “any issue that keeps the CEO awake at night”.

Tracking them in job postings allows us to see which companies are leading on specific issues and which are on the heels – and the important thing is where the market is expanding and shrinking.

In which countries is the highest growth in job advertisements in the railway industry?

The fastest growing country was Hungary, which saw 0% of all fintech job postings in the three months ending March 2021, rising to 35.7% in the three months ending March this year.

It is followed by Spain (28.6 percentage points), Australia (-4.1) and Brazil (-4.1).

The leading country for fintech roles in the railway industry is Hungary, which accounted for 35.7% of all advertised roles in the three months ending March.

Which cities are the biggest centers for fintech workers in the railway industry?

About 35.7% of all fintech roles in the railway industry were announced in Budapest (Hungary) in the three months ending March.

It is followed by Valencia (Spain) with 14.3%, Barcelona (Spain) with 14.3% and Aventura (USA) with 7.1%.

Related companies

Previous articleUS Navy’s Portsmouth Naval Shipyard Opens New Super Flood Pool
Next articleThe FDA has extended the review period for Pfizer-Myovant’s sNDA for Myfembree